IL17A and Crohn disease: In a trial using a secukinumab and brodalumab for treating Crohn’s disease, symptoms worsened in patients receiving anti-IL-17 antibodies, leading to early termination of the trial.149,150,259 As discussed above, IL-17 also plays an important role in establishing host barriers and maintaining mucosal integrity.